Abstract
Given the broad treatment options, risk stratification of pulmonary embolism is a highly desirable component of management. The ideal tool identifies patients at risk of death from the original or recurrent pulmonary embolism. Using all-cause death in the first 30-days after pulmonary embolism diagnosis as a surrogate, clinical parameters, biomarkers, and radiologic evidence of right ventricular dysfunction and strain are predictive. However, no study has demonstrated improved mortality rates after implementation of a risk stratification strategy to guide treatment. Further research should use better methodology to study prognosis and test new management strategies in patients at high risk for death.
Original language | English |
---|---|
Pages (from-to) | 437-448 |
Number of pages | 12 |
Journal | Critical Care Clinics |
Volume | 36 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2020 |
Externally published | Yes |
Keywords
- Biomarkers
- Clinical assessment
- Mortality
- Prognosis
- Pulmonary embolism
- Risk stratification